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polyomavirus infection following renal transplantation. We searched PubMed, Embase, and the
Cochrane Central Register of Controlled Trials for research articles published prior to January
2015 using keywords such as “fluoroquinolone,” “BK viremia,” and “renal transplantation.” We
extracted all types of study published in English. The primary outcome was BK viremia and vir-
uria at 1 year post-transplantation. Secondary outcomes were BK virus-associated nephropathy
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including a total of 1477 participants with a mean duration of fluoroquinolone prophylaxis of
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tion following renal transplantation.
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Kidney transplantation remains the treatment of choice for
patients with end-stage renal disease. Acute rejection rates
have been dramatically reduced with the development of
potent immunosuppressant regimens; however, other
major complications of kidney transplantation, such as BK
polyomavirus (BKV) infection, are emerging [1].
Primary BKV infection generally occurs in childhood and
persists in the genitourinary tract, remaining quiescent in
the majority of immunocompetent hosts. Latent BKV in-
fections in the host or graft reactivate following trans-
plantation and are initially observed in the urine (BK viruria),
then in the blood (BK viremia), and ultimately in the allo-
graft [BK virus nephropathy (BKVN)] [2]. Up to 60% and 30% of
kidney transplant recipients develop viruria and viremia,
respectively [3,4]. A reported 5.5e8% of infected patients
progress to BKVN, leading to graft dysfunction and graft loss
in more than 50% and 25% of cases, respectively [5,6].
Although antiviral agents, such as cidofovir, leflunomide,
fluoroquinolone antibiotics, and intravenous immunoglob-
ulins, have demonstrated efficacy in treating BKV infection,
definitive evidence is lacking [2,7e9]. The mainstay of
treatment in patients with BK viremia is decreasing the
amount of immunosuppression [10,11]. However, immuno-
suppression reductions must be cautiously conducted
because reduced immunosuppression may increase the risk
of acute rejection episodes [12,13], and patients often
remain viremic [14,15] and long-term outcomes are un-
certain [16].
Altogether, there is a substantial clinical need to iden-
tify efficacious therapies for preventing BKV infection,
particularly in transplant recipients with recurrent episodes
of rejection (e.g., highly sensitized patients). In theory,
fluoroquinolones represent an appealing therapeutic option
for preventing BK viremia. Fluoroquinolones inhibit bacte-
rial DNA replication by targeting the bacterial enzymes,
gyrase, and topoisomerase IV. This effect is relevant as the
large T antigen of BKV possesses a helicase function that is
essential for replication [17,18]. A previous in vitro analysis
demonstrated that fluoroquinolones can inhibit BKV DNA
replication [19].
A retrospective study involving 185 renal transplants
reported that patients receiving a 1-month postoperative
course of fluoroquinolones had a significantly lower fre-
quency of BK viremia (22.5% vs. 4%, p Z 0.03) and BKVN
(8.75% vs. 4%) compared with untreated patients [20].
However, a recent randomized controlled trial (RCT)
demonstrated that administration of levofloxacin for
3 months was not associated with lower BK viremia [hazard
ratio (HR), 0.68; 95% confidence interval (CI), 0.26e1.76] or
viruria (HR, 0.91; 95% CI, 0.51e1.63) but was instead
associated with an increased risk of resistant BKV infection
[risk ratio (RR), 1.75; 95% CI, 1.01e2.98] [21]. Several other
studies have reported conflicting results [22,23]. There-
fore, we conducted this systematic review and meta-
analysis to evaluate the efficacy of fluoroquinolones in
preventing BKV infection following renal transplantation
and provide more convincing evidence to support or reject
the use of prophylaxis protocols comprising fluo-
roquinolones following renal transplantation.Materials and methods
Types of studies, participants, interventions, and
outcomes
In this systematic review and meta-analyses, we included
RCTs and observational studies of fluoroquinolone prophy-
laxis in BKV infection following renal transplantation. We
included studies with participants aged >18 years who
underwent either deceased donor renal transplantation or
living donor renal transplantation. Recipients receiving
fluoroquinolone without any other prophylaxis for BK
viremia prevention were included.
The primary outcome was the incidence of BK viremia or
viruria at 1 year post-transplantation. The secondary out-
comes were the incidences of BKVN, BKVN-associated graft
failure, and fluoroquinolone-resistant BKV infection.Search methods for identification of studies
An electronic search of PubMed, Embase, and the Cochrane
Central Register of Controlled Trials was performed up to
January 2015. The search strategy was limited to humans
and included the following keywords: “fluoroquinolones,”
“levofloxacin,” “ciprofloxacin,” “quinolones,” or “BK pol-
yoma viremia” with “renal transplantation,” “kidney
transplantation,” or “renal allograft.”
The electronic search was supplemented with a manual
search of the reference lists of retrieved articles and other
reviews to identify other potential studies. Our search
included reference lists of articles, reviews, and editorials
irrespective of language, publication status, or blinding.
When required, we attempted to contact researchers to
obtain data missing from original publications.Selection of studies
We included comparative studies such as RCTs and obser-
vational studies. Two review authors undertook the selec-
tion of studies. Review authors independently reviewed the
titles and abstracts of all the articles identified by the
literature search. Where titles or abstracts did not provide
sufficient information, full-text versions were obtained.
The same two review authors independently assessed
whether studies met the inclusion criteria. In cases where
full-text versions did not provide sufficient information,
corresponding authors were contacted for further details.Data extraction and management
A standardized data collection form was designed to
extract data regarding study ID (author name and year of
publication), study design, type of allograft (living or
deceased), sex, mean or median age, immunosuppressive
therapy, fluoroquinolone prophylaxis regimen, dose, dura-
tion, and length of follow up. Moreover, we extracted data
on graft failure, infection, and BKVN. The two review au-
thors independently extracted patient demographics,
characteristics, follow-up duration, and primary and
Electronic search: 113 
Hand search: 0 
24 duplicates removed 
Unique citations: 89 
Case report:8 
No control arm: 25 
Review: 31 
Not kidney transplantation: 5 
Study protocol: 2 
Miscellaneous:10 
Eligible studies: 8 
Conference abstract: 5 Full text available: 3 
Figure 1. Flowchart of included studies.
154 T.-R. Song et al.secondary outcomes. In case of discrepancy, the opinion of
a third reviewer was sought to reach consensus.
Measures of treatment effect
Descriptive statistics were conducted for demographic
data. The primary and secondary outcomes (BK viremia,
viruria, BKVN, graft failure, and fluoroquinolone-resistant
BKV infection) were reported as RRs with 95% confidence
intervals. As the majority of included studies were retro-
spective cohort studies, a random effect model was
generated. All p values < 0.05 were considered statistically
significant.
Assessment of heterogeneity
The degree of clinical heterogeneity was analyzed on the
basis of the dose, duration, type of study, and length of
follow up between the two groups. Statistical heterogene-
ity was analyzed by Cochran Q statistic with theTable 1 Basic information of included studies.
Authors Year Study design Fluoroquinolone
Gabardi et al [20] 2010 Retrospective Ciprofloxacin (250 mg
Levofloxacin (250 mg
Wojciechowski
et al [25]
2012 Retrospective Ciprofloxacin (250 mg
Jason et al [26] 2013 Retrospective Ciprofloxacin (250 mg
Min et al [22] 2013 Retrospective Ciprofloxacin (250 mg
Patel et al [27] 2013 Retrospective Ciprofloxacin (500 mg
Eng et al [23] 2014 Retrospective Ciprofloxacin (250 mg
Galen et al [24] 2014 Prospective RCT Levofloxacin (500 mg
Knoll et al [21] 2014 Prospective RCT Levofloxacin (500 mg
b.i.d. Z bis in die (twice a day); q.d. Z quaque die (once a day); Rsignificance level a set at 0.05. The statistic I2, which is
derived from Q, was used to describe the percentage of
variation across studies because of heterogeneity rather
than chance.
All analyses were performed using Review Manager
(RevMan, ver. 5.0; Cochrane Collaboration, Oxford,
England).Results
Description of studies
Overall, eight studies, comprising 1477 renal transplants,
were included in the meta-analysis according to the Quality
of Reporting of Meta-Analyses guideline criteria (Figure 1).
These included two RCTs reporting on a direct comparison
of fluoroquinolone versus no treatment or placebo [21,24]
and six retrospective cohort studies [20,22,23,25e27]. Un-
fortunately, full texts were available for only three studies
[20,21,25], with the remaining five studies presented as
conference abstracts. Although we attempted to contact
the corresponding authors, no response was received. One
retrospective study utilized both ciprofloxacin and levo-
floxacin, with the remaining studies using single fluo-
roquinolone therapy (ciprofloxacin or levofloxacin). Results
regarding dose, duration, diagnostic criteria of BK viremia,
viruria, and follow-up duration are reported in Table 1.Assessment of risk of bias
The risk of bias was assessed using the NewcastleeOttawa
scale [28] in all retrospective studies (Table 2). All six
retrospective cohort studies were accordingly rated 9/9
[20,22,23,25e27]. Two RCTs investigated the use of fluo-
roquinolone in preventing BK viremia in renal recipients
[21,24]. Only one trial described the process of randomi-
zation and allocation concealment and conducted an
intention-to-treat analysis and was, therefore, considered
to be of “A” quality [24]. The other study could not be
assessed because of the limited information provided in the
conference abstract and incomplete study [21].Therapy
duration (mo)
BK viremia
(copies/mL)
BK viruria
(copies/mL)
Follow up
(y)
b.i.d.) 1 500 d >1
q.d.)
b.i.d.) 1 500 1000 1
q.d.) 6 d d 1
q.d.) 1 >500 d 1
q.d.) 3 d d 1
b.i.d.) 1 >1000 d 1
daily) 6 d d 1
daily) 3 >25 500 1
CT Z randomized controlled trial.
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Fluoroquinolone and BKV in renal transplant 155Heterogeneity
The included studies were clinically heterogeneous in study
design, dose, duration, and diagnostic criteria of BK viremia
or viruria. Although statistical heterogeneity (I2 > 50%) was
not noted for all outcomes, high heterogeneity was still
considered to be present.
Primary outcome measure: BK viremia
Two RCTs performed a direct comparison of the two stra-
tegies for BKV infection prevention and reported no dif-
ference in the incidence of BK viremia at 1 year post-
transplantation [21,24]. Four cohort studies corroborated
the conclusions of this RCT [20e24,26,27]. A higher inci-
dence of BK viremia was even noted in those who received
any fluoroquinolone compared with those who received
none (14.4% vs. 7.1%, pZ 0.04), and patients who received
fluoroquinolone for 30 days had a higher incidence of BK
viremia compared with those who received either fluo-
roquinolone for less than 30 days or did not receive fluo-
roquinolone (16.5% vs. 7.6% or 7.1%; p Z 0.02) [23].
However, two cohort studies reported that patients
receiving fluoroquinolone prophylaxis were significantly
less likely to develop BK viremia (4% vs. 22.5%, pZ 0.03 and
10% vs. 25.7%, p Z 0.045, respectively) [20,22]. When
processable data were incorporated, fluoroquinolone pro-
phylaxis was not found to decrease the risk of BK viremia
following kidney transplant at 1 year post-transplantation
(RR, 0.83; 95% CI, 0.47e1.47; Figure 2). Furthermore, the
administration of fluoroquinolone for 1 month (RR, 0.62;
95% CI, 0.14e2.74), 3 months (RR, 0.71; 95% CI, 0.38e1.30),
and 6 months (RR, 1.23; 95% CI, 0.45e3.36) had no pro-
tective effect on BK viremia at 1 year post-transplantation.
Primary outcome measure: BK viruria
Wojciechowski et al [25] reported BK viruria in 38% and 32%
of patients in the control and ciprofloxacin prophylaxis
groups, respectively (pZ 0.1738). Knoll et al [21] reported
BK viruria in 22 patients (29.0%) in the levofloxacin group
and 26 patients (33.3%) in the placebo group (RR, 0.87; 95%
CI, 0.54e1.39). However, these data could not be combined
for further analysis.
Secondary outcome measure: BKVN
Galen et al [24] reported one case of biopsy-proven BKVN in
the control arm, with no cases in the fluoroquinolone arm.
Furthermore, four cohort studies observed no difference in
the BKVN occurrence during follow up [20,25e27]. Meta-
analysis demonstrated no difference in the incidence of
BKVN between the groups (RR, 0.68; 95% CI, 0.29e1.59;
Figure 3).
Secondary outcome measure: graft loss due to
BKVN
Two studies reported five cases of graft loss due to BKVN in
the control arms and no graft loss in the fluoroquinolone
Study or Subgroup
1.6.1 1 month
Eng et al [23]
Gabardi et al [20]
Min et al [22]  
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 1.34; Chi² = 11.06, df = 2 (p = 0.004); i² = 82%
Test for overall effect: z = 0.63 (p  = 0.53)
1.6.2 3 months
Knoll et al [21]
Patel et al [27] 
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.01, df  = 1 (p = 0.94); i²  = 0%
Test for overall effect: z = 1.11 (p  = 0.27)
1.6.3 6 months
Galen et al [24]
Jason et al [26]
Subtotal (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.12, df  = 1 (p  = 0.73); i² = 0%
Test for overall effect: z  = 0.41 (p  = 0.68)
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.28; Chi² = 12.23, df = 6 (p= 0.06); i²  = 51%
Test for overall effect:  z  = 0.65 (p  = 0.51)
Test for subgroup differences: Not applicable
Events
19
1
4
24
6
7
13
4
3
7
44
Total
132
25
39
196
76
80
156
14
59
73
425
Events
13
36
19
68
9
30
39
3
3
6
113
Total
183
160
74
417
78
247
325
15
59
74
816
Weight (%)
21.3
6.8
15.6
43.7
16.0
19.3
35.2
11.7
9.3
21.1
100.0
M-H, Random, 95% CI
2.03 [1.04, 3.96]
0.18 [0.03, 1.24]
0.40 [0.15, 1.09]
0.62 [0.14, 2.74]
0.68 [0.26, 1.83]
0.72 [0.33, 1.58]
0.71 [0.38, 1.30]
1.43 [0.39, 5.28]
1.00 [0.21, 4.75]
1.23 [0.45, 3.36]
0.83 [0.47, 1.47]
oitaRksiRoitaRksiRlortnoCenoloniuqoroulF
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 2. BK viremia at 1 year between the fluoroquinolone prophylaxis arm and the control arm. CI Z confidence interval.
156 T.-R. Song et al.arms [20,21]. Pooled analysis demonstrated no difference
in the incidence of graft loss between the groups (RR, 0.50;
95% CI, 0.06e4.27; Figure 4).
Secondary outcome measure: fluoroquinolone-
resistant infection
Wojciechowski et al [25] reported no difference in the
incidence of ciprofloxacin-resistant infections at 12 months
post-transplantation between the two groups (4.7% vs.
7.7%, p Z 0.53), with no difference in the incidence of
other fluoroquinolone-resistant infections at 12 months
post-transplantation (p Z 0.45). Similarly, Knoll et al [21]
reported a comparable incidence of quinolone-resistant
infection in the levofloxacin and placebo groups (46.7%vs. 32.6%; RR, 1.43;95% CI, 0.81e2.50). However, when
restricted to isolates usually sensitive to quinolones, the
proportion of resistant isolates was much higher in the
levofloxacin group than in the placebo group (58.3% vs.
33.3%; RR, 1.75; 95% CI, 1.01e2.98). Pooled analysis
demonstrated no difference in the incidence of
fluoroquinolone-resistant infection between the groups
(RR, 1.08; 95% CI, 0.64e1.83; Figure 5).
Discussion
BKV infection remains a major issue in renal transplantation
as it affects up to 30% of kidney recipients and often leads
to unfavorable consequences. As there are no effective
therapeutic treatments for disease caused by BKV
Study or Subgroup
Gabardi et al [20]   
Galen et al [24]
Jason et al [26]
Patel et al [27]
Wojciechowski et al [25]
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 3.99, df = 4 (p = 0.41);i² = 0%
Test for overall effect: z = 0.88 (p = 0.38)
Events
1
0
3
3
1
8
Total
25
14
59
80
130
308
Events
14
1
1
10
5
31
Total
160
15
59
247
106
587
Weight (%)
18.1
7.3
14.3
44.6
15.7
100.0
M-H, Random, 95% CI
0.46 [0.06, 3.33]
0.36 [0.02, 8.07]
3.00 [0.32, 28.02]
0.93 [0.26, 3.28]
0.16 [0.02, 1.37]
0.68 [0.29, 1.59]
oitaRksiRoitaRksiRlortnoCenoloniuqoroulF
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 3. BK virus-associated nephropathy at 1 year between the fluoroquinolone prophylaxis arm and the control arm.
CI Z confidence interval.
Fluoroquinolone and BKV in renal transplant 157infection, strategies aimed toward the prevention of BK
viremia would have considerable clinical benefit in this
population. A previous study reported in vitro activity of
fluoroquinolones against BKV [19], and convincing evidence
from hematopoietic stem cell transplant recipients has
indicated that ciprofloxacin prophylaxis results in a signifi-
cant reduction in the incidence of BKV-associated hemor-
rhagic cystitis [8,29]. However, studies of kidney transplant
recipients have yielded inconsistent results. Our pooled
analysis revealed that the use of fluoroquinolone prophy-
laxis does not reduce the incidence of BKV infection.
Similarly, rates of BKVN and graft loss due to BKVN were
similar between the groups.
Several risk factors for BK viremia, including patient age,
male gender, diabetes, white race, induction therapy, and
acute rejection, have been identified. Gabardi et al [20]
reported favorable results following the use of fluo-
roquinolone prophylaxis, whereas two other studies did notStudy or Subgroup
Gabardi et al [20]
Knoll et al [21]
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.10, df = 1 (p = 0.75); i² = 0%
Test for overall effect: z = 0.63 (p = 0.53)
Events
0
0
0
Total
25
76
101
Events
4
1
5
Total
160
78
238
Weight (
54.8
45.2
100.0
lortnoCenoloniuqoroulF
Figure 4. Graft failure due to BK virus-associated nephropathy
arm. CI Z confidence interval.[21,25]. Induction therapy may have contributed to this
discrepancy, with 73%, 53%, and 27.3% of patients receiving
antithymocyte globulin in the studies by Gabardi et al [20],
Wojciechowski et al [25], and Knoll et al [21], respectively.
The rate of acute rejection may also have had an effect,
with Gabardi et al [20] and Knoll et al [21] reporting that
18.9% and 7.1% of patients, respectively, developed acute
rejection episodes, whereas the rate of acute rejection was
not reported by Wojciechowski et al [25]. These results
indicate that in patients with higher risk of BKV infection,
fluoroquinolone prophylaxis may have a partially protective
effect. However, a well-designed and organized RCT is
required to confirm this hypothesis.
In general, the most intense period of immunosuppres-
sion occurs during the first 3e6 months post-
transplantation, with peak BK viremia and the onset of
BKVN typically occurring at 3 months [30] and 9e12 months
post-transplantation [11], respectively. Of note,%) M-H, Random, 95% CI
0.69 [0.04, 12.41]
0.34 [0.01, 8.27]
0.50 [0.06, 4.27]
oitaRksiRoitaRksiR
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
between the fluoroquinolone prophylaxis arm and the control
Study or Subgroup
Knoll et al [21]
Patel et al [27]
Wojciechowski et al [25]
Total (95% CI)
Total events
Heterogeneity: Tau² = 0.00; Chi² = 0.80, df = 2 (p = 0.67); i² = 0%
Test for overall effect: z = 0.31 (p = 0.76)
Events
14
2
10
26
Total
76
80
130
286
Events
15
7
5
27
Total
78
247
106
431
Weight (%)
63.5
11.4
25.2
100.0
M-H, Random, 95% CI
0.96 [0.50, 1.85]
0.88 [0.19, 4.16]
1.63 [0.58, 4.62]
1.08 [0.64, 1.83]
oitaRksiRoitaRksiRlortnoCenoloniuqoroulF
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours experimental Favours control
Figure 5. Fluoroquinolone-resistant infection between the fluoroquinolone prophylaxis arm and the control arm.
CI Z confidence interval.
158 T.-R. Song et al.Wojciechowski et al [25] reported that patients receiving
250 mg ciprofloxacin two times daily for 30 days had a
significantly lower risk of developing BK viremia (0.161 vs.
0.065, pZ 0.0378) and viruria (0.303 vs. 0.146, PZ 0.0067)
at 3 months post-transplantation; however, this difference
disappeared at 12 months post-transplantation for both
viremia (0.297 vs. 0.261, pZ 0.6061) and viruria (0.437 vs.
0.389, p Z 0.5363). Min et al [22] reported that peak BKV
replication appears to be delayed by approximately
1 month in patients receiving ciprofloxacin prophylaxis (5th
month vs. 4th month). Longer courses of therapy designed
to extend throughout the most intensive period of immu-
nosuppression may be useful in lowering the incidence of
BKV infection. However, when studies were stratified ac-
cording to therapy duration, fluoroquinolone prophylaxis of
3-month and 6-month duration did not reduce the incidence
of BKV infection, indicating that longer courses of therapy
may not be beneficial.
Fluoroquinolone prophylaxis has been posited as a po-
tential method of decreasing the incidence of urinary tract
infections following kidney transplantation. A retrospective
study evaluated the incidence of urinary tract infections
before and after implementation of a 1-month course of
ofloxacin prophylaxis (200 mg every other day). This study
demonstrated that ofloxacin was independently associated
with a reduction in the incidence of urinary tract infections
[odds ratio (OR), 0.31; p Z 0.02] and acute pyelonephritis
(OR, 0.21; p Z 0.045). The therapeutic effect of ofloxacin
prophylaxis was maintained for the 1st year post-
transplantation [31]. However, concerns regarding fluo-
roquinolone therapy remain. First, Knoll et al [21] reported
that seven cases of tendinitis occurred, of which six were in
the levofloxacin group, thereby demonstrating the potential
for concomitant complication following fluoroquinolone
administration. Second, long-term use of fluoroquinolone
may induce drug-resistant infections as demonstrated by
Knoll et al [21] who reported an approximately twofold in-
crease in the rates of resistance among quinolone-sensitive
organisms in the levofloxacin group. Patel et al [27] reported
several cases of Clostridium difficile infections and reduced
sensitivity of Escherichia coli and Klebsiella pneumoniae to
many antibiotics. Although this study did not demonstrate ahigher incidence of fluoroquinolone-resistant infections,
these results have significant implications for clinical prac-
tice regarding the management of infections in kidney
transplant recipients.
Our study has several limitations. First, the majority of
included studies were retrospective cohort studies. Study
designs, patient baseline characteristics, therapy dosages
and durations, and criteria of BK viremia varied among
included studies such that heterogeneity among studies
could not be eliminated by generating a random-effect
model alone. Furthermore, five conference abstracts pro-
vided inadequate information, making it impossible to
analyze raw data for individual patients, which is now
considered the optimal approach. Finally, the majority of
studies did not include BK viruria as a primary measure-
ment, with a proportion of studies not providing this in-
formation. However, viremia may be a more relevant
clinical outcome because monitoring protocols adjusted to
immunosuppression levels are usually based on viremia.
During the pathogenesis of BKVN, the detection of viral
reactivation in the urine usually precedes the development
of both viremia and nephropathy. BK viruria, the first step
of BKV infection, may be a higher priority component of
screening protocols for evaluating the efficacy of fluo-
roquinolone prophylaxis.
In conclusion, This meta-analysis demonstrated that the
prophylactic use of fluoroquinolones is not effective for
preventing BK viremia in kidney transplant recipients and
does not reduce the incidence of BKVN or graft loss. These
findings do not support the use of fluoroquinolones for the
prevention of post-transplantation BKV infection.
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